A new reporting system will be available on December 5, 2019. To avoid errors, reports may only be made through the current system until December 2, 2019.
Update - Unavailability and start or stop of commercialisation: no reporting possible between December 2 and 5, 2019
Information session about PharmaStatus, the new application for reporting and consulting unavailability and start or stops of commercialisation
Via the new online application PharmaStatus, marketing authorization holders can notify the FAMHP of unavailability and start or stop of commercialization of a drug. Marketing authorization holders are invited to an information session on November 18, 2019.
Limited availability of intravenous immunoglobulins: recommendations to the attention of hospital pharmacists and the physician-specialists within hospitals where there is an availability problem.
Through possible limited availability of intravenous immunoglobulins, there is a threat of a shortage in some hospitals in Belgium. The Federal Agency for Medicines and Health Products (FAMHP) is giving recommendations for hospital pharmacists and physician-specialists within the hospitals.
After successful consideration among the FAMHP, the National Institute for Health and Disability Insurance (RIZIV-INAMI) and the manufacturer Therabel, the manufacturer has decided to continue to produce the drug Marevan. The FAMHP calls on pharmacists and patients to not order unnecessary inventories of the drug so that the drug will remain available for all patients.